Lannett announced that it received approval from the FDA of its abbreviated new drug application, or ANDA, for Aspirin and extended-release Dipyridamole capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals. Total U.S. sales of Aspirin and extended-release Dipyridamole capsules, 25 mg/200 mg, was approximately $174.6M for the 12 months ended January, according to IQVIA, although actual generic market values are expected to be lower.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.